BiotechTube

Bupivacaine HCI without epinephrine + HTX-011

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Post-Operative Pain

Conditions

Post-Operative Pain, Lumbar Laminectomy

Trial Timeline

Apr 7, 2022 → Aug 26, 2022

NCT ID
NCT04911062

About Bupivacaine HCI without epinephrine + HTX-011

Bupivacaine HCI without epinephrine + HTX-011 is a phase 2 stage product being developed by Heron Therapeutics for Post-Operative Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT04911062. Target conditions include Post-Operative Pain, Lumbar Laminectomy.

What happened to similar drugs?

4 of 12 similar drugs in Post-Operative Pain were approved

Approved (4) Terminated (0) Active (8)
✅Sugammadex + Neostigmine + Atropine + Rocuronium + Fentanyl + Propofol + SevofluraneMerckApproved
✅granisetron + granisetronRocheApproved
✅Parecoxib SodiumPfizerApproved
✅RopivacaineLundbeckApproved
🔄Test naproxen sodium tablet + Commercial naproxen sodium tablet + Commercial naproxen sodium liquid gels capsule + Placebo tabletJohnson & JohnsonPhase 3
🔄Test acetaminophen + Commercial acetaminophen + Commercial ibuprofen + PlaceboJohnson & JohnsonPhase 3
🔄Comparator: MK0517 + Comparator: ondansetronMerckPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04911062Phase 2Completed

Competing Products

18 competing products in Post-Operative Pain

See all competitors
ProductCompanyStageHype Score
QutenzaAstellas PharmaPre-clinical
26
Test naproxen sodium tablet + Commercial naproxen sodium tablet + Commercial naproxen sodium liquid gels capsule + Placebo tabletJohnson & JohnsonPhase 3
40
Test acetaminophen + Commercial acetaminophen + Commercial ibuprofen + PlaceboJohnson & JohnsonPhase 3
40
Paracetamol injection + Normal Saline injection + Morhpine PCAJiangsu Hengrui MedicinePhase 2/3
38
AGN-151607 + PlaceboAbbViePhase 2
35
Comparator: MK0517 + Comparator: ondansetronMerckPhase 3
40
Sugammadex + Neostigmine + Atropine + Rocuronium + Fentanyl + Propofol + SevofluraneMerckApproved
39
Aprepitant + Placebo to Aprepitant + Ondansetron + Placebo to match ondansetronMerckPhase 2
35
granisetron + granisetronRocheApproved
43
Parecoxib SodiumPfizerApproved
43
lyricaPfizerPhase 3
40
Placebo + Pregabalin + PregabalinPfizerPhase 1
29
Methylnaltrexone + PlaceboPfizerPhase 3
40
HSK16149 capsule + PlaceboHaisco Pharmaceutical GroupPhase 2
35
RopivacaineLundbeckApproved
40
Sufentanil NanoTab PCA System/15 mcg + morphine IV PCATalpheraPhase 3
30
Sufentanil NanoTab PCA System/15 mcg + Placebo Sufentanil NanoTab PCA SystemTalpheraPhase 3
30
Sufentanil Tablet 30 mcg + Placebo TabletTalpheraPhase 3
30